Human NK cells activated by EBV+ lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells

OncoImmunology

Volumn 4, Issue 3, 2015, Pages 1-13

  Sánchez Martínez, Diego ^a,b   Azaceta, Gemma ^c   Muntasell, Aura ^d   Aguiló, Nacho ^b   Núñez, David ^a,b   Gálvez, Eva Ma ^a,e   Naval, Javier ^a,b   Anel, Alberto ^a,b   Palomera, Luis ^c   Vilches, Carlos ^h   Marzo, Isabel ^a,b   Villalba, Martín ^f,g   Pardo, Julián ^a,b,i  

^a INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e INSTITUTO DE CARBOQUÍMICA   (Spain)

^f INSERM   (France)

^g MONTPELLIER UNIVERSITY HOSPITAL   (France)

^h HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

ⁱ FUNDACIÓN ARAID   (Spain)

Author keywords

Apoptosis; B lymphoblastoid cell line; Haematological neoplasia; Multidrug acquired resistance; NK cells

Indexed keywords

CASPASE 3; GRANZYME B; INTERLEUKIN 2; PROTEIN BAK; PROTEIN BAX; PROTEIN MCL 1; PROTEIN P53;

APOPTOSIS; ARTICLE; BLOOD CANCER CELL; CELL TRANSFORMATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; EPSTEIN BARR VIRUS INFECTION; EXOCYTOSIS; HUMAN; HUMAN CELL; JURKAT CELL LINE; LYMPHOBLASTOID CELL; LYMPHOCYTE ACTIVATION; MUTATION; NATURAL KILLER CELL; PROTEIN EXPRESSION;

EID: 84954481360     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.991613     Document Type: Article

References (55)

1. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26:1324-37.; PMID:17322918; http://dx.doi.org/10.1038/sj.onc.1210220
2. Lindner SE, Wissler M, Grunder A, Aumann K, Ottina E, Peintner L, Brauns-Schubert P, Preiss F, Herzog S, Borner C, et al. Increased leukocyte survival and accelerated onset of lymphoma in the absence of MCL-1 S159-phosphorylation. Oncogene 2013; 33:5221-5224.; PMID:242135 75; http://dx.doi.org/10.1038/onc.2013.469
3. McKeithan TW, Rowley JD, Shows TB, Diaz MO. Cloning of the chromosome translocation breakpoint junction of the t(14;19) in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1987; 84:9257-60.; PMID:3122218; http://dx.doi.org/10.1073/pnas.84.24.9257
4. Traver D, Akashi K, Weissman IL, Lagasse E. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity 1998; 9:47-57.; PMID:9697835; http://dx.doi.org/10.1016/S1074-7613(00)80587-7
5. Zhou P, Qian L, Bieszczad CK, Noelle R, Binder M, Levy NB, Craig RW. Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood 1998; 92:3226-39.; PMID:9787159
6. Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, Izon DJ, Zuber J, Rappaport AR, Herold MJ, et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev 2012; 26:120-5.; PMID:22279045; http://dx.doi.org/10.1101/gad.182980.111
7. Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008; 111:846-55.; PMID:17928528; http://dx.doi.org/10.1182/blood-2007-05-089037
8. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, Wang HG, Zhang X, Bullrich F, Croce CM, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998; 91:3379-89.; PMID:9558396
9. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463:899-905.; PMID:20164920; http://dx.doi.org/10.1038/nature08822
10. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12:269-81.; PMID:22437939; http://dx.doi.org/10.1038/nri3191
11. Villalba M, Rathore MG, Lopez-Royuela N, Krzywinska E, Garaude J, Allende-Vega N. From tumor cell metabolism to tumor immune escape. Int J Biochem Cell Biol 2013; 45:106-13.; PMID:22568930; http://dx.doi.org/10.1016/j.biocel.2012.04.024
12. Pardo J, Wallich R, Martin P, Urban C, Rongvaux A, Flavell RA, Müllbacher A, Borner C, Simon MM. Granzyme B-induced cell death exerted by ex vivo CTL: discriminating requirements for cell death and some of its signs. Cell Death Differ 2008; 15:567-79.; PMID:18064039; http://dx.doi.org/10.1038/sj.cdd.4402289
13. Roder JC, Karre K, Kiessling R. Natural killer cells. Prog Allergy 1981; 28:66-159.; PMID:6166015
14. Herberman RB, Holden HT. Natural cell-mediated immunity. Adv Cancer Res 1978; 27:305-77.; PMID:356546; http://dx.doi.org/10.1016/S0065-230X(08)60936-7
15. Ljunggren HG, Karre K. In search of the ’missing self’: MHC molecules and NK cell recognition. Immunol Today 1990; 11:237-44.; PMID:2201309; http://dx.doi.org/10.1016/0167-5699(90)90097-S
16. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22:633-40.; PMID:11698225; http://dx.doi.org/10.1016/S1471-4906(01)02060-9
17. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9:495-502.; PMID:18425106; http://dx.doi.org/10.1038/ni1581
18. Bottino C, Moretta L, Moretta A. NKcell activating receptors and tumor recognition in humans. Curr Top Microbiol Immunol 2006; 298:175-82.; PMID:16323416; http://dx.doi.org/10.1007/3-540-27743-9_9
19. Chan CJ, Andrews DM, Smyth MJ. Can NK cells be a therapeutic target in human cancer? Eur J Immunol 2008; 38:2964-8.; PMID:18979512; http://dx.doi.org/10.1002/eji.200838764
20. Ruggeri L, Mancusi A, Burchielli E, Perruccio K, Aversa F, Martelli MF, Velardi A. Natural killer cell recognition of missing self and haploidentical hematopoietic transplantation. Semin Cancer Biol 2006; 16:404-11.; PMID:16916611; http://dx.doi.org/10.1016/j.semcancer.2006.07.007
21. Willemze R, Rodrigues CA, Labopin M, Sanz G, Michel G, Socie G, Rio B, Sirvent A, Renaud M, Madero L, et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009; 23:492-500.; PMID:19151783; http://dx.doi.org/10.1038/leu.2008.365
22. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, Stern M, Pende D, Perruccio K, Burchielli E, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007; 110:433-40.; PMID:17371948; http://dx.doi.org/10.1182/blood-2006-07-038687
23. Velardi A. Natural killer cell alloreactivity 10 years later. Curr Opin Hematol 2012; 19:421-6.; PMID:22954728; http://dx.doi.org/10.1097/MOH.0b013e3283590395
24. Fuchs EJ, Huang XJ, Miller JS. HLA-haploidentical stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2009; 16:S57-63.; PMID:19892024; http://dx.doi.org/10.1016/j.bbmt.2009.10.032
25. Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, Moreno A, Dupont B, Hsu KC, Baxter-Lowe LA, et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 2008; 143:641-53.; PMID:18950462; http://dx.doi.org/10.1111/j.1365-2141.2008.07340.x
26. Curti A, Ruggeri L, D’Addio A, Bontadini A, Dan E, Motta MR, Trabanelli S, Giudice V, Urbani E, Martinelli G, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 2011; 118:3273-9.; PMID:21791425; http://dx.doi.org/10.1182/blood-2011-01-329508
27. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, Bell T, Pui CH, Leung W. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010; 28:955-9.; PMID:20085940; http://dx.doi.org/10.1200/JCO.2009.24.4590
28. Cho D, Campana D. Expansion and activation of natural killer cells for cancer immunotherapy. Korean J Lab Med 2009; 29:89-96.; PMID:19411773; http://dx.doi.org/10.3343/kjlm.2009.29.2.89
29. Perussia B, Ramoni C, Anegon I, Cuturi MC, Faust J, Trinchieri G. Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines. Nat Immun Cell Growth Regul 1987; 6:171-88.; PMID:2960890
30. Sanchez-Martinez D, Krzywinska E, Rathore MG, Saumet A, Cornillon A, Lopez-Royuela N, Martínez-Lostao L, Ramirez-Labrada A, Lu ZY, Rossi JF, et al. Alltrans retinoic acid (ATRA) induces miR-23a expression, decreases CTSC expression and granzyme B activity leading to impaired NK cell cytotoxicity. Int J Biochem Cell Biol 2014; 49:42-52.; PMID:24440757; http://dx.doi.org/10.1016/j.biocel.2014.01.003
31. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, Eldridge P, Leung WH, Campana D. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009; 69:4010-7.; PMID:19383914; http://dx.doi.org/10.1158/0008-5472.CAN-08-3712
32. Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, Singh H, Hurton L, Maiti SN, Huls MH, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLOS ONE 2012; 7:e30264.; PMID:22279576; http://dx.doi.org/10.1371/journal.pone.0030264
33. Childs RW, Berg M. Bringing natural killer cells to the clinic: ex vivo manipulation. HEMATOLOGY 2013; 2013:234-46.; PMID:24319186; http://dx.doi.org/10.1182/asheducation-2013.1.234
34. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, Anderson D, Eisenmann J, Grabstein K, Caligiuri MA. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994; 180:1395-403.; PMID:7523571; http://dx.doi.org/10.1084/jem.180.4.1395
35. Lee N, Llano M, Carretero M, Ishitani A, Navarro F, Lopez-Botet M, et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A 1998; 95:5199-204.; PMID:9560253; http://dx.doi.org/10.1073/pnas.95.9.5199
36. Shimizu Y, Geraghty DE, Koller BH, Orr HT, DeMars R. Transfer and expression of three cloned human non- HLA-A,B,C class I major histocompatibility complex genes in mutant lymphoblastoid cells. Proc Natl Acad Sci U S A 1988; 85:227-31.; PMID:3257565; http://dx.doi.org/10.1073/pnas.85.1.227
37. Kurago ZB, Lutz CT, Smith KD, Colonna M. NK cell natural cytotoxicity and IFN-gamma production are not always coordinately regulated: engagement of DX9 KIRC NK cells by HLA-B7 variants and target cells. J Immunol 1998; 160:1573-80.; PMID:9469412
38. Núñez D, Domingo MP, Sánchez-Martínez D, Cebolla V, Chiou A, Velázquez-Campoy A, Pardo J, Galvez EM, Recombinant production of human ICAM-1 chimeras by single step on column refolding and purification. Proc Biochem 2013; 48:708-15.
39. Romee R, Foley B, Lenvik T, Wang Y, Zhang B, Ankarlo D, Luo X, Cooley S, Verneris M, Walcheck B, et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 2013; 121:3599-608.; PMID:23487023; http://dx.doi.org/10.1182/blood-2012-04-425397
40. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, Augugliaro R, Moretta L, Moretta A. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complexrestricted tumor cell lysis. J Exp Med 1998; 187:2065-72.; PMID:9625766; http://dx.doi.org/10.1084/jem.187.12.2065
41. De Miguel D, Basanez G, Sanchez D, Malo PG, Marzo I, Larrad L, Naval J, Pardo J, Anel A, Martinez-Lostao L. Liposomes decorated with Apo2L/TRAIL overcome chemoresistance of human hematologic tumor cells. Mol Pharm 2013; 10:893-904.; PMID:23331277; http://dx.doi.org/10.1021/mp300258c
42. Sedelies KA, Ciccone A, Clarke CJ, Oliaro J, Sutton VR, Scott FL, Silke J, Susanto O, Green DR, Johnstone RW, et al. Blocking granule-mediated death by primary human NK cells requires both protection of mitochondria and inhibition of caspase activity. Cell Death Differ 2008; 15:708-17.; PMID:18202705; http://dx.doi.org/10.1038/sj.cdd.4402300
43. Gyrd-Hansen M, Darding M, Miasari M, Santoro MM, Zender L, Xue W, Tenev T, da Fonseca PC, Zvelebil M, Bujnicki JM, et al. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat Cell Biol 2008; 10:1309-17.; PMID:18931663; http://dx.doi.org/10.1038/ncb1789
44. Locatelli F, Pende D, Mingari MC, Bertaina A, Falco M, Moretta A, Moretta L. Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Front Immunol 2013; 4:15.; PMID:23378843; http://dx.doi.org/10.3389/fimmu.2013.00015
45. Berg M, Lundqvist A, McCoy P, Samsel L, Fan Y, Tawab A, Childs R. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009; 11:341-55.; PMID:19308771; http://dx.doi.org/10.1080/14653240902807034
46. Kay NE, Zarling JM. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 1984; 63:305-9.; PMID:6607080
47. Veuillen C, Aurran-Schleinitz T, Castellano R, Rey J, Mallet F, Orlanducci F, Pouyet L, Just-Landi S, Coso D, Ivanov V, et al. Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy. J Clin Immunol 2011; 32:632-46.; PMID:22318393; http://dx.doi.org/10.1007/s10875-011-9624-5
48. Mahrus S, Craik CS. Selective chemical functional probes of granzymes A and B reveal granzyme B is a major effector of natural killer cell-mediated lysis of target cells. Chem Biol 2005; 12:567-77.; PMID:15911377; http://dx.doi.org/10.1016/j.chembiol.2005.03.006
49. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, Yun GH, Fautsch SK, McKenna D, Le C. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105:3051-7.; PMID:15632206; http://dx.doi.org/10.1182/blood-2004-07-2974
50. Kroger N, Zabelina T, Berger J, Duske H, Klyuchnikov E, Binder T, Stübig T, Hilde-brandt Y, Atanackovic D, Alchalby H, et al. Donor KIR haplotype B improves progression- free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia 2011; 25:1657-61.; PMID:21647155; http://dx.doi.org/10.1038/leu.2011.138
51. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15:1126-32.; PMID:19228717; http://dx.doi.org/10.1158/1078-0432.CCR-08-0144
52. Vandenberg CJ, Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 2013; 121:2285-8.; PMID:23341542; http://dx.doi.org/10.1182/blood-2013-01-475855
53. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19:202-8.; PMID:23291630; http://dx.doi.org/10.1038/nm.3048
54. Vogler M, Hamali HA, Sun XM, Bampton ET, Dinsdale D, Snowden RT, Dyer MJ, Goodall AH, Cohen GM. BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood 2011; 117:7145-54.; PMID:21562047; http://dx.doi.org/10.1182/blood-2011-03-344812
55. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097-100.; PMID:11896281; http://dx.doi.org/10.1126/science.1068440